Core Viewpoint - Sun Yan, a pioneer in China's oncology field, passed away at the age of 97, leaving a significant legacy in cancer treatment and research [2]. Group 1: Contributions to Oncology - Sun Yan was a founding figure in the development of oncology in China, advocating for a comprehensive treatment approach and leading the establishment of the discipline from scratch [2]. - He initiated nearly 80 clinical trials and trained over a thousand oncology professionals, significantly contributing to the growth of the field [2]. - Sun Yan was involved in the development of over 30 new drugs, including the first small-molecule targeted anti-cancer drug in China, demonstrating his impact on drug innovation [2]. Group 2: Recognition and Awards - Throughout his career, Sun Yan received numerous accolades, including the National Science and Technology Progress Award (First Class) and the Chinese Physician Award, highlighting his contributions to medical science [2][5]. - He was elected as an academician of the Chinese Academy of Engineering in 1999, further solidifying his status in the medical community [2]. Group 3: Legacy and Influence - Following his passing, many in the oncology community expressed their condolences and shared memories, emphasizing his role in founding the Chinese Society of Clinical Oncology (CSCO) and fostering international collaboration [3]. - His efforts in organizing national cancer cause investigations and creating the first "Malignant Tumor Atlas" were pivotal in advancing the understanding of cancer in China [3]. - Sun Yan's dedication to education and mentorship has left a lasting impact, with many professionals in the field crediting him for their foundational training and guidance [4][5].

Core Viewpoint - The passing of Sun Yan, a pioneer in clinical oncology in China, marks a significant loss for the field, as he was instrumental in establishing and advancing oncology treatment and research in the country [1][2]. Group 1: Contributions to Oncology - Sun Yan was a founding figure in China's oncology field, advocating for comprehensive treatment approaches and leading the development of over 30 new drugs, including the first small-molecule targeted cancer drug with complete independent intellectual property rights in China, Alectinib [1][2]. - He initiated nearly 80 clinical trials and trained over a thousand oncology professionals, significantly contributing to the growth of oncology as a discipline in China [1][2]. - His efforts in drug development and clinical research not only advanced medical science but also positively impacted local economies, exemplified by his role in alleviating poverty in the Dingxi region through the promotion of local pharmaceutical products [1]. Group 2: Legacy and Recognition - Sun Yan's legacy includes the establishment of the Chinese Society of Clinical Oncology (CSCO), which he helped to found, promoting collaboration and communication with international organizations [2]. - He received numerous accolades, including the National Science and Technology Progress Award and the title of Advanced Worker in the National Health System, reflecting his significant contributions to the field [3]. - His dedication to education and mentorship has left a lasting impact, with many professionals in the oncology field crediting him for their foundational training and guidance [3].